Vancouver, British Columbia--(Newsfile Corp. - April 4, 2024) - Cathay Visions Enterprises Ltd. (the "Acquiror") acquired 110,000 common shares (each a "Common Share") of Optimi Health Corp. (the "Issuer")...
Announces the completion of its proprietary preclinical MDMA drug candidate OPTI-MHCL for use in drug ...
Announces the expansion of its sales network in Canada. To further scale the sales and distribution ...
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial plan...
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll clinical...
FN Media Group Presents Microsmallcap.com Market Commentary  New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...
/PRNewswire/ -- A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer's disease, announcing recently that it has gotten...
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian company that makes natural, scalable, and easy-to-get psychedelic and functional mushrooms, as well as synthetic formulations, to help people...
Announces that it has completed what it believes to be the largest legal natural psilocybin harvest ...
Announces that it has entered into an agreement with Avida Global, a privately-held UK-based producer ...